	US 12,453,740 B2
	Nucleic acids for cell recognition and integration
Leon Bernal-Mizrachi, Atlanta, GA (US); and Matthew Charles Tindall, Piedmont, CA (US)
Assigned to EMORY UNIVERSITY, Atlanta, GA (US); and KODIKAZ THERAPEUTIC SOLUTIONS, INC., New York, NY (US)
Filed by Emory University, Atlanta, GA (US); and Kodikaz Therapeutic Solutions, Inc., New York, NY (US)
Filed on Mar. 24, 2021, as Appl. No. 17/211,622.
Application 17/211,622 is a continuation of application No. PCT/US2019/052680, filed on Sep. 24, 2019.
Claims priority of provisional application 62/875,887, filed on Jul. 18, 2019.
Claims priority of provisional application 62/736,323, filed on Sep. 25, 2018.
Prior Publication US 2021/0315916 A1, Oct. 14, 2021
Int. Cl. A61K 48/00 (2006.01); A61K 31/711 (2006.01); A61K 45/06 (2006.01); A61K 51/02 (2006.01)

CPC A61K 31/711 (2013.01) [A61K 45/06 (2013.01); A61K 48/0058 (2013.01); A61K 51/02 (2013.01); C12N 2800/90 (2013.01)]

21 Claims

1. A pharmaceutical composition comprising a nucleic acid construct, a cargo covalently attached to the nucleic acid construct, and a pharmaceutically-acceptable excipient, wherein:

(a) the cargo is a therapeutic cargo or diagnostic cargo;

(b) the nucleic acid construct comprises a first deoxyribonucleic acid sequence that induces cell type-preferential uptake of the nucleic acid construct by a cell from a pre-selected tissue, wherein the first deoxyribonucleic acid sequence comprises at least 70% sequence identity to the nucleic acid sequence set forth in:

(i) SEQ ID NO: 282;

(ii) SEQ ID NO: 209;

(iii) SEQ ID NO: 268;

(iv) SEQ ID NO: 277;

(v) SEQ ID NO: 203;

(vi) SEQ ID NO: 211;

(vii) SEQ ID NO: 216;

(viii) SEQ ID NO: 230;

(ix) SEQ ID NO: 241; or

(x) SEQ ID NO: 251; and